Stock Analysis, Dividends, Split History

PHH / PHH Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price10.88
Volume66,700.00
Market Cap ($M)354.48
Enterprise Value ($M)-98.52
Book Value ($M)489.00
Book Value / Share15.01
Price / Book0.72
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Shares Outstanding 32,551,759
Preferred Stock Shares Outstanding 0
Common Stock Shares Outstanding 32,547,258
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.35
Return on Assets (ROA)-0.06
Return on Equity (ROE)-0.18
Balance Sheet (mrq) ($M)
Assets1,442.00
Liabilities953.00
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Revenues456,000,000.00
Disposal Group Including Discontinued Operation Revenue0.00
Net Income-194.00
Earnings Per Share Basic And Diluted-4.62
Cash Flow Statement (mra) ($M)
Cash From Operations303.00
Cash from Investing197.00
Cash from Financing197.00
Identifiers and Descriptors
CUSIP693320202
Central Index Key (CIK)77776
Related CUSIPS
693320952 693320902 069332020

Split History

Stock splits are used by PHH Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

How Trump's Supreme Court nominee ruled on hot-button issues | Euronews

2018-07-11 euronews
Supreme Court nominee Judge Brett Kavanaugh has written almost 300 opinions on a range of issues over his 12 years serving on the federal appellate court. In a piece for SCOTUSblog, Edith Roberts noted that, "Kavanaugh generally brings a pragmatic approach to judging, although his judicial philosophy is conservative, and he has applied principles of textualism and originalism espoused by the late Justice Antonin Scalia.

Stocks making the biggest moves premarket: GE, LEN, FDS, HOG, VALE & more

2018-06-26 cnbc
General Electric – GE announced plans to spin off its health-care unit, selling 20 percent and distributing the rest to shareholders, and it will also exit its stake in Baker Hughes over the next two to three years. Today is also the first time since 1907 that the Dow Jones Industrial Average will trade without GE as a member, with the stock replaced in the Dow by Walgreens Boots Alliance. (96-0)

CFPB's Mulvaney set to drop PHH case | American Banker

2018-06-06 americanbanker
The Consumer Financial Protection Bureau is poised to dismiss its case against PHH Corp., a nonbank mortgage lender and servicer whose appeal of a $109 million penalty led to a four-year legal battle over whether the agency's single-director structure was constitutional. (1-0)

Ocwen (OCN) Stock Up 5.1% on Q1 Earnings Beat, Costs Down

2018-05-03 zacks
Shares of Ocwen Financial Corporation (OCN - Free Report) gained nearly 5.1% following the release of first-quarter 2018 results. Earnings were 2 cents per share while the Zacks Consensus Estimate was a loss of 33 cents. Also, the figure reflected improvement from the prior-year quarter’s loss of 26 cents. Results primarily benefited from a decrease in expenses, which resulted from the company’s efforts to sell Mortgage Servicing Rights (MSR) and trim operations to focus on the core business. (11-0)

Ocwen Financial's (OCN) CEO Ronald Faris on Q1 2018 Results - Earnings Call Transcript

2018-05-02 seekingalpha
Good day, ladies and gentlemen, and welcome to the Ocwen Financial’s First Quarter 2018 Earnings Call. At this time, all participants are in listen-only mode. Later we will conduct a question-and-answer session, and instructions will follow at that time. [Operator Instructions] As a reminder, this call may be recorded. I would now like to introduce your host for today’s conference, Mr. Stephen Swett. (75-0)

CUSIP: 693320202